

GLAXOSMITHKLINE PLC  
Form 6-K  
January 13, 2017

FORM 6-K

SECURITIES AND EXCHANGE COMMISSION  
Washington D.C. 20549

Report of Foreign Issuer

Pursuant to Rule 13a-16 or 15d-16 of  
the Securities Exchange Act of 1934

For period ending 13 January 2017

GlaxoSmithKline plc  
(Name of registrant)

980 Great West Road, Brentford, Middlesex, TW8 9GS  
(Address of principal executive offices)

Indicate by check mark whether the registrant files or  
will file annual reports under cover Form 20-F or Form 40-F

Form 20-F  Form 40-F

--

Indicate by check mark whether the registrant by furnishing the  
information contained in this Form is also thereby furnishing the  
information to the Commission pursuant to Rule 12g3-2(b) under the  
Securities Exchange Act of 1934.

Yes  No

GlaxoSmithKline plc (the 'Company')

Transaction notification

1. Details of PDMR/person closely associated with them ('PCA')
  - a) Name Sir Andrew Witty
  - b) Position/status Chief Executive Officer
  - c) Initial notification/ amendment Initial notification
2. Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor
  - a) Name GlaxoSmithKline plc
  - b) LEI 5493000HZTVUYLO1D793
3. Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted
  - a) Description of the financial instrument
 

Ordinary shares of 25 pence each ('Ordinary Shares')

ISIN: GB0009252882
  - b) Nature of the transaction
 

Acquisition of Ordinary Shares following the re-investment of dividends paid to shareholders on 12 January 2017, on shares held within an ISA.
  - c) Price(s) and volume(s)
 

Price(s)	Volume(s)
£15.7648	107
Aggregated information	
n/a (single transaction)	
  - d) Aggregated volume Price
  - e) Date of the transaction 2017-01-13
  - f) Place of the transaction London Stock Exchange (XLON)

1. Details of PDMR/person closely associated with them ('PCA')
  - a) Name Mr D S Redfern
  - b) Position/status Chief Strategy Officer
  - c) Initial notification/ amendment Initial notification
2. Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor
  - a) Name GlaxoSmithKline plc
  - b) LEI 5493000HZTVUYLO1D793
3. Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted
  - a) Description of the financial instrument

Ordinary shares of 25 pence each ('Ordinary Shares')

ISIN: GB0009252882  
Acquisition of Ordinary Shares following the re-investment of dividends paid to shareholders on 12 January 2017, on shares held within an ISA.

b) Nature of the transaction

c) Price(s) and volume(s)

Price(s)	Volume(s)
£15.7648	21
n/a (single transaction)	

Aggregated information

d) Aggregated volume Price

e) Date of the transaction

2017-01-13

f) Place of the transaction

London Stock Exchange (XLON)

1. Details of PDMR/person closely associated with them ('PCA')

a) Name	Mrs V A Whyte
b) Position/status	Company Secretary
c) Initial notification/ amendment	Initial notification

2. Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

a) Name	GlaxoSmithKline plc
b) LEI	5493000HZTVUYLO1D793

3. Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted

Ordinary shares of 25 pence each ('Ordinary Shares')

a) Description of the financial instrument

ISIN: GB0009252882

Acquisition of Ordinary Shares following the re-investment of dividends paid to shareholders on 12 January 2017, on shares held within an ISA.

b) Nature of the transaction

c) Price(s) and volume(s)

Price(s)	Volume(s)
£15.7648	18

d) Aggregated information

n/a (single transaction)

- Aggregated volume Price
- e) Date of the transaction 2017-01-13
- f) Place of the transaction London Stock Exchange (XLON)
1. Details of PDMR/person closely associated with them ('PCA')
- a) Name Lady C Witty
- b) Position/status PCA of Sir Andrew Witty (Chief Executive Officer)
- c) Initial notification/ amendment Initial notification
2. Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor
- a) Name GlaxoSmithKline plc
- b) LEI 5493000HZTVUYLO1D793
3. Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted
- Ordinary shares of 25 pence each ('Ordinary Shares')
- a) Description of the financial instrument ISIN: GB0009252882
- b) Nature of the transaction Acquisition of Ordinary Shares following the re-investment of dividends paid to shareholders on 12 January 2017, on shares held within an ISA.
- c) Price(s) and volume(s) Price(s) Volume(s)  
£15.7648 49
- Aggregated information
- d) n/a (single transaction)
- Aggregated volume Price
- e) Date of the transaction 2017-01-13
- f) Place of the transaction London Stock Exchange (XLON)
1. Details of PDMR/person closely associated with them ('PCA')
- a) Name Mr J P Witty
- b) Position/status PCA of Sir Andrew Witty (Chief Executive Officer)
- c) Initial notification/ amendment Initial notification
2. Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor
- a) Name GlaxoSmithKline plc
- b) LEI 5493000HZTVUYLO1D793

Edgar Filing: GLAXOSMITHKLINE PLC - Form 6-K

Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted

- |  |  |
|--|--|
| a) Description of the financial instrument | Ordinary shares of 25 pence each ('Ordinary Shares')   |
|  | ISIN: GB0009252882   |
| b) Nature of the transaction               | Acquisition of Ordinary Shares following the re-investment of dividends paid to shareholders on 12 January 2017, on shares held within an ISA. |
| c) Price(s) and volume(s)                  | Price(s)      Volume(s)  |
| Aggregated information                     | £15.7648      60   |
| d) Aggregated volume                       | n/a (single transaction)   |
| e) Date of the transaction                 | 2017-01-13   |
| f) Place of the transaction                | London Stock Exchange (XLON)   |

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorised.

GlaxoSmithKline plc  
(Registrant)

Date: January 13, 2017

By: VICTORIA WHYTE-----

Victoria Whyte  
Authorised Signatory for and on  
behalf of GlaxoSmithKline plc